SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes in Individuals With Type 2 Diabetes: A Comparative Effectiveness Review

Highlights

• SGLT2 inhibitors (SGLT2i) demonstrated a 19% lower 5-year risk of chronic kidney disease (CKD) compared to GLP-1 receptor agonists (GLP-1RA) in a large-scale target trial emulation.
• The burden of acute kidney injury (AKI) was significantly lower in SGLT2i initiators, with a 12% reduction in mean cumulative counts over 5 years.
• While SGLT2i showed superior protection against eGFR decline and kidney failure, GLP-1RAs were associated with slightly better outcomes regarding albuminuria reduction and overall mortality.
• Renoprotective benefits of SGLT2i were most pronounced in individuals without preexisting kidney disease, suggesting a powerful role in primary prevention.

Background

Type 2 diabetes (T2D) remains the leading cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) globally. For decades, inhibition of the renin-angiotensin-aldosterone system (RAAS) was the solitary pharmacological pillar for renoprotection. The landscape changed dramatically with the advent of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA).

Large cardiovascular outcome trials (CVOTs)—such as EMPA-REG OUTCOME for empagliflozin and LEADER for liraglutide—incidentally revealed profound renal benefits. Subsequent renal-specific trials like DAPA-CKD and CREDENCE solidified SGLT2i as a cornerstone of nephrology. Similarly, the FLOW trial recently demonstrated the renal efficacy of semaglutide. However, clinicians often face a dilemma: which class should be prioritized for kidney protection when glycemic control is established? To date, no head-to-head randomized clinical trials (RCTs) have directly compared SGLT2i and GLP-1RA for kidney outcomes, leaving a critical gap in evidence-based decision-making.

Key Content

Target Trial Emulation: Methodological Rigor

In the absence of direct RCT data, the study by Jensen et al. (2026) utilized a target trial emulation design using Danish nationwide registries. This approach minimizes the inherent biases of observational research (such as immortal time bias and healthy user bias) by mimicking the design of a prospective trial. The study followed 36,279 SGLT2i initiators and 18,782 GLP-1RA initiators, all of whom were previously treated with metformin, providing a high-power comparison in a real-world clinical setting.

Chronic Kidney Disease (CKD) Outcomes

The primary finding of this synthesis is the superior effectiveness of SGLT2i in preventing hard renal endpoints. The composite CKD outcome—defined as a 40% reduction in estimated glomerular filtration rate (eGFR), severe albuminuria, or kidney failure—showed a clear divergence in risk.

Over a 5-year follow-up, the risk of CKD was 6.7% for SGLT2i versus 8.2% for GLP-1RA. The risk ratio (RR) of 0.81 (95% CI, 0.76-0.87) indicates a 19% relative risk reduction favoring SGLT2i. This suggests that for every 1,000 patients treated with SGLT2i instead of GLP-1RA, approximately 15 fewer CKD events would occur over five years.

Acute Kidney Injury (AKI) Burden

Historically, concerns were raised about SGLT2i and the potential for AKI due to osmotic diuresis and initial ‘eGFR dip.’ However, this comparative evidence refutes those concerns. The 5-year mean cumulative count (MCC) of AKI was 25.2 per 100 individuals for SGLT2i vs. 28.7 for GLP-1RA (MCC ratio 0.88). The reduction in AKI burden with SGLT2i was consistent across various patient subgroups, reinforcing the safety profile of this class regarding acute renal hemodynamic changes.

Secondary Outcomes: Albuminuria and Mortality

Interestingly, the data showed a slight divergence when examining secondary outcomes. GLP-1RA initiators experienced slightly better results in the reduction of albuminuria and overall mortality. This suggests that while SGLT2i are more potent at preserving eGFR and preventing structural failure, GLP-1RAs may offer distinct pathways for reducing vascular inflammation and potentially providing a broader survival benefit in certain populations. This highlights the possibility that combination therapy (SGLT2i + GLP-1RA) may be the ultimate strategy for high-risk patients.

Subgroup Analysis and Primary Prevention

A critical insight from the latest evidence is the efficacy of SGLT2i in primary prevention. The reduction in CKD and AKI was most pronounced in individuals who did *not* have preexisting kidney disease at baseline. This suggests that the early introduction of SGLT2i—immediately following or alongside metformin—could significantly delay the onset of diabetic kidney disease (DKD) more effectively than starting with a GLP-1RA.

Expert Commentary

From a mechanistic perspective, the superiority of SGLT2i in preventing CKD is likely driven by their unique ability to restore tubuloglomerular feedback. By increasing sodium delivery to the macula densa, SGLT2i induce afferent arteriolar vasoconstriction, thereby reducing intraglomerular pressure—a primary driver of diabetic nephropathy.

While GLP-1RAs also possess renoprotective properties—likely mediated through anti-inflammatory pathways, natriuresis, and reduction in oxidative stress—they do not appear to have the same immediate hemodynamic impact on the glomerulus as SGLT2i.

Clinical guidelines (such as the 2024 ADA Standards of Care and KDIGO 2024) already emphasize SGLT2i for patients with T2D and CKD. However, the study by Jensen et al. provides a compelling argument for prioritizing SGLT2i even earlier in the disease course for primary renal protection. A potential controversy remains regarding the “eGFR dip” seen with SGLT2i; however, experts now view this as a sign of successful glomerular pressure reduction rather than injury, as corroborated by the lower AKI rates in this study.

Limitations of the current evidence include the non-randomized nature of real-world data, which may still harbor unmeasured confounding (e.g., physician preference for GLP-1RA in patients with obesity or higher cardiovascular risk). Furthermore, the 5-year horizon, while substantial, may not fully capture the lifetime renal trajectory of T2D patients.

Conclusion

In individuals with type 2 diabetes, SGLT2 inhibitors offer superior protection against both chronic kidney disease progression and acute kidney injury compared to GLP-1 receptor agonists. While GLP-1RAs remain essential for cardiovascular risk management and glycemic control, SGLT2i should be considered the first-line agent for renal preservation. Future research should focus on the synergistic effects of combining these two classes, which may potentially eliminate the risk of kidney failure in T2D patients if initiated early enough in the disease process.

References

• Jensen SK, Heide-Jørgensen U, Andersen IT, et al. SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes in Individuals With Type 2 Diabetes. JAMA Intern Med. 2026;186(3):353-361. PMID: 41557360.
• Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-1446. PMID: 32970396.
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295-2306. PMID: 30990260.
• Mann JFE, Ørsted DD, Brown-Frandsen K, et al. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377(9):839-848. PMID: 28854331.